Switch theme
Sign up to access all valuation multiples
Anika Therapeutics Inc is an orthopedic medicines company. It is committed to improving the lives of patients with degenerative orthopedic diseases and traumatic conditions with clinically meaningful therapies. The company focuses on orthopedics, including osteoarthritis pain management, regenerative solutions, soft tissue repair, and bone preserving joint technologies. Geographically, it derives a majority of its revenue from the United States and also has its presence in Europe and Other countries.
1992
288
LTM Revenue $118M
LTM EBITDA $13.7M
$167M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Anika Therapeutics has a last 12-month revenue of $118M and a last 12-month EBITDA of $13.7M.
In the most recent fiscal year, Anika Therapeutics achieved revenue of $120M and an EBITDA of $3.0M.
Anika Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Anika Therapeutics valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $167M | $120M | XXX | XXX | XXX |
| Gross Profit | $93.6M | $103M | XXX | XXX | XXX |
| Gross Margin | 56% | 86% | XXX | XXX | XXX |
| EBITDA | -$11.2M | $3.0M | XXX | XXX | XXX |
| EBITDA Margin | -7% | 3% | XXX | XXX | XXX |
| Net Profit | -$14.9M | -$82.7M | XXX | XXX | XXX |
| Net Margin | -9% | -69% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Anika Therapeutics's stock price is $14.
Anika Therapeutics has current market cap of $197M, and EV of $167M.
See Anika Therapeutics trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $167M | $197M | XXX | XXX | XXX | XXX | $0.11 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Anika Therapeutics has market cap of $197M and EV of $167M.
Anika Therapeutics's trades at 1.4x LTM EV/Revenue multiple, and 12.2x LTM EBITDA.
Analysts estimate Anika Therapeutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Anika Therapeutics and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $167M | XXX | XXX | XXX |
| EV/Revenue | 1.4x | XXX | XXX | XXX |
| EV/EBITDA | 55.4x | XXX | XXX | XXX |
| P/E | -3.5x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | -57.0x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpAnika Therapeutics's NTM/LTM revenue growth is -2%
Anika Therapeutics's revenue per employee for the last fiscal year averaged $0.4M, while opex per employee averaged $0.3M for the same period.
Over next 12 months, Anika Therapeutics's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Anika Therapeutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Anika Therapeutics and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | -28% | XXX | XXX | XXX | XXX |
| EBITDA Margin | 3% | XXX | XXX | XXX | XXX |
| EBITDA Growth | -127% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | 0% | XXX | XXX | XXX | XXX |
| Revenue per Employee | $0.4M | XXX | XXX | XXX | XXX |
| Opex per Employee | $0.3M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 21% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 68% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Anika Therapeutics acquired XXX companies to date.
Last acquisition by Anika Therapeutics was XXXXXXXX, XXXXX XXXXX XXXXXX . Anika Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Anika Therapeutics founded? | Anika Therapeutics was founded in 1992. |
| Where is Anika Therapeutics headquartered? | Anika Therapeutics is headquartered in United States of America. |
| How many employees does Anika Therapeutics have? | As of today, Anika Therapeutics has 288 employees. |
| Who is the CEO of Anika Therapeutics? | Anika Therapeutics's CEO is Dr. Cheryl R. Blanchard, PhD. |
| Is Anika Therapeutics publicy listed? | Yes, Anika Therapeutics is a public company listed on NAS. |
| What is the stock symbol of Anika Therapeutics? | Anika Therapeutics trades under ANIK ticker. |
| When did Anika Therapeutics go public? | Anika Therapeutics went public in 1993. |
| Who are competitors of Anika Therapeutics? | Similar companies to Anika Therapeutics include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Anika Therapeutics? | Anika Therapeutics's current market cap is $197M |
| What is the current revenue of Anika Therapeutics? | Anika Therapeutics's last 12-month revenue is $118M. |
| What is the current EBITDA of Anika Therapeutics? | Anika Therapeutics's last 12-month EBITDA is $13.7M. |
| What is the current EV/Revenue multiple of Anika Therapeutics? | Current revenue multiple of Anika Therapeutics is 1.4x. |
| What is the current EV/EBITDA multiple of Anika Therapeutics? | Current EBITDA multiple of Anika Therapeutics is 12.2x. |
| What is the current revenue growth of Anika Therapeutics? | Anika Therapeutics revenue growth between 2023 and 2024 was -28%. |
| Is Anika Therapeutics profitable? | Yes, Anika Therapeutics is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
